Compare DFNS & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFNS | EVAX |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United States | Denmark |
| Employees | 15 | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.2M | 23.6M |
| IPO Year | N/A | 2020 |
| Metric | DFNS | EVAX |
|---|---|---|
| Price | $37.95 | $3.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | ★ 23.3M | 12.0K |
| Earning Date | 04-09-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $328.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.04 | $2.52 |
| 52 Week High | $91.00 | $12.15 |
| Indicator | DFNS | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 58.90 | 46.42 |
| Support Level | $0.30 | $2.97 |
| Resistance Level | $91.00 | $3.61 |
| Average True Range (ATR) | 13.65 | 0.13 |
| MACD | 3.10 | 0.03 |
| Stochastic Oscillator | 49.58 | 59.21 |
T3 Defense Inc is a holding company that acquires and operates mission-critical defense businesses involved in national security programs. It focuses on manufacturers with tough customer relationships and solid order backlogs, often capacity-and resource-constrained and specialized areas such as drones and autonomous vehicles, counter-drone systems, main manufacturing, tactical robotics, and AI software and system integration. Through disciplined acquisitions, centralized capital and ideas, and decentralized day-to-day operations, it aims to strengthen essential defense capabilities and build long-term value.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.